Dihydrocodeine

Dihydrocodeine is a semi-<a href="/facts/Chemical_synthesis/3KXsVVwC">synthetic</a> opioid <a href="/facts/Analgesic/xLj4XBcq">analgesic</a> prescribed for pain or severe <a href="/facts/Dyspnea/1jBfFzxU">dyspnea</a>, or as an <a href="/facts/Antitussive/2Qe0AjMx">antitussive</a>, either alone or compounded with <a href="/facts/Paracetamol/SNDfQWcf">paracetamol</a> (acetaminophen) (as in <a href="/facts/Co-dydramol/l6faBM0r">co-dydramol</a>) or <a href="/facts/Aspirin/opMK4qLk">aspirin</a>. It was developed in Germany in 1908 and first marketed in 1911.
Commonly available as tablets, solutions, elixirs, and other oral forms, dihydrocodeine is also available in some countries as an injectable solution for deep subcutaneous and intra-muscular administration. As with <a href="/facts/Codeine/lr7WHXmX">codeine</a>, intravenous administration should be avoided, as it could result in <a href="/facts/Anaphylaxis/F9IDQxeL">anaphylaxis</a> and life-threatening <a href="/facts/Pulmonary_edema/sVS5UDxl">pulmonary edema</a>. In the past, dihydrocodeine suppositories were used. Dihydrocodeine is available in suppository form on prescription. Dihydrocodeine is used as an alternative to codeine and similarly belongs to step 2 of the <a href="/facts/Pain_ladder/952QtEXm">WHO analgesic ladder</a>.
It was first described in 1911 and approved for medical use in 1948. Dihydrocodeine was developed during the search for more effective cough medication, especially to help reduce the spread of tuberculosis, pertussis, and pneumonia in the years from c.a. 1895 to 1915. It is similar in chemical structure to codeine.

Dihydrocodeine open-in-new

Dihydrocodeine